Search results
Massive study identifies new biomarkers for renal cancer subtypes, improving diagnosis...
Medical Xpress· 1 week agoThe findings lay the groundwork to identify therapeutic targets in non-clear-cell renal cell carcinomas. Renal < ...
New PET agent provides same-day imaging for clear cell renal cell carcinoma patients
Medical Xpress· 6 days agoA novel investigational PET imaging agent can rapidly and accurately visualize lesions in clear cell renal cell cancer (ccRCC) patients according to new research published in the May issue of ...
Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?
Motley Fool via Yahoo Finance· 1 day agoExelixis Exelixis specializes in cancer medicines. It earned quite a reputation thanks to its most...
Iovance (IOVA) Gears Up for Q1 Earnings: Here's What to Expect
Zacks via Yahoo Finance· 1 week agoInvestors' focus will likely be on Iovance's (IOVA) progress with its ongoing commercial launch for...
Moderna plants new solid tumor trials for cancer vaccine, weeds PD-1 work after review
FierceBiotech· 2 weeks agoModerna detailed plans for its individual neoantigen cancer vaccine in a first-quarter earnings...
Iovance (IOVA) Q1 Earnings Surpass, Sales Lag Estimates
Zacks via Yahoo Finance· 3 days agoIovance (IOVA) reports mixed first-quarter results. Shares gain on encouraging initial demand for...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 2 hours agoCemacabtagene Ansegedleucel (Cema-Cel) Expanded CD19 Oncology Rights to Include all EU Member States and the United Kingdom, Reinforcing Company’s Conviction in the Unique Opportunity in Large B Cell Lymphoma (LBCL) and Relapsed/Refractory (R/
Afinitor interactions: Other medications, alcohol, and more
Medical News Today· 1 week agoAfinitor has interactions with some other drugs and certain supplements. Before you start treatment...
Targeting CXCR4 impaired T regulatory function through PTEN in renal cancer patients - British...
Nature· 1 week agoTregs trafficking is controlled by CXCR4. In Renal Cell Carcinoma (RCC), the effect of the new CXCR4 antagonist, R54, was explored in ...
Leads Biolabs is Proud to Announce its Participation in the 2024 ASCO Annual Meeting with One Oral...
WPRI Providence· 18 hours agoThe 2024 American Society of Clinical Oncology (ASCO) Annual Meeting will be held in Chicago from May 31 to June 4, 2024. Leads Biolabs will present the exciting clinical data on its four innovative clinical programs at the ASCO meeting.